Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Dogs aid paralysis study
dog and human
Nineteen paraplegic dogs were recruited for the study.
Findings could lead to personalised treatments for spinal cord injuries

Research by North Carolina State University involving paraplegic dogs has revealed that a one-size fits all approach is not ideal for treating spinal cord injuries and courses of treatment should instead be diverse.

The findings could lead to personalised treatments for spinal cord injuries, and hopefully better outcomes for canine and potentially human patients.

Led by Natasha Olby, professor of neurology at NC State University, the research team conducted a clinical trial involving the drug 4-AP and a derivative of the drug called t-butly.

4-AP has been tested on humans for spinal cord injury, and is currently used as a treatment for multiple sclerosis. T-butyl has not been tested clinically on humans. Both drugs work by helping damaged nerves transmit signals.

Nineteen paraplegic dogs were recruited for the study.  All of the dogs had suffered similar spinal cord injuries, and had been injured long enough to rule out any hope of unaided recovery.  A placebo and both drugs were administered to the dogs, each for a two-week block of randomly assigned time, first to determine whether the drugs were effective, and then to see whether or not there was a difference in efficacy between the two medications.

Professor Olby said: "The question quickly went from 'Do the drugs work?' to 'Why aren't they having similar effects across the board?'. And there are many possible factors to consider – some of the dogs may not have any axons left for the drug to act on, or it may depend upon how long they’ve been paralyzed or even whether or not they have a genetic predisposition to respond to this treatment.”

Professor Olby is now focussed on determining how best to identify patient populations that will respond best to the treatment.

She adds: “There is no doubt that either or both of these medications can have an amazing effect on the right patient – but now we have to do the work of finding out what conditions make a patient the right one. If we can do that, we may save both patients and owners a lot of unnecessary frustration.”

The study, “Potassium channel antagonists 4-aminopyridine and the t-butyl carbamate derivative of 4-aminopyridine improve hind limb function in chronically non-ambulatory dogs; a blinded, placebo-controlled trial,” is published in PLOS One.

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.